<< Back
Stereotaxis to Report Fourth Quarter and Full Year 2015 Financial Results on February 22, 2016
February 8, 2016 at 6:30 AM EST

ST. LOUIS, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday, February 22, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What: Stereotaxis fourth quarter and full year 2015 financial results conference call            
When: Monday, February 22nd at 4:30 p.m. Eastern Time (1:30 p.m. PT)  
Dial In Number: To access the live call, dial 888-417-8465 (US and Canada) or 719-325-2329 (International) and give the participant pass code 4685179.
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com   
Call Replay: A replay of the call will be available approximately one hour following the end of the call through 7:30 p.m. ET on February 29, 2016.  
Replay Numbers: 888-203-1112 (US and Canada)  
  719-457-0820 (International)  
  Replay passcode: 4685179  

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.

The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono ICE catheter manipulator, V-Loop variable loop catheter manipulator, and V-CAS catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com

Press Contact:
Martin Stammer
Chief Financial Officer

Investor Contact:
Todd Kehrli / Jim ByersMKR Group, Inc.

Primary Logo

Stereotaxis, Inc.
© Copyright Stereotaxis 2019